SecBot SecBot
PRESS-RELEASE ·Filed May 27, 2026

MDWD

MediWound Ltd.
BEARISH
Impact 5/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor EscharEx Phase III enrollment updates and the timing of BARDA-related revenue recognition in H2 2026, which is critical to achieving the $24-26M full-year guidance. Cash runway of $45M supports operations into 2027 but burn rate warrants attention.

DirectionBearish
Confidencehigh
Horizonmonths

EscharEx

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
If the Phase 3 VALUE trial reads out positive in 2H 2027, an FDA submission could follow in 2027-2028, with potential approval in 2028-2029 at the earliest, assuming no delays.
Next catalyst
None dated

What to watchThe next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$14.33
T+0 close · May 27, 2026 · via day close
Latest settled
−8.48%
T+60 · $13.12
Vs SPY
−10.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $14.33entry
  2. T+1 · 6mo ago +1.60%α +1.05% · $14.56
  3. T+5 · 6mo ago −4.19%α −4.66% · $13.73
  4. T+20 · 5mo ago +1.81%α +3.72% · $14.59
  5. T+60 · 3mo ago −8.48%α −10.36% · $13.12

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MediWound reported Q1 2026 revenue of $1.5M, down 62% YoY from $4.0M, and a net loss of $0.23 per share, wider than the $0.07 loss a year ago. The revenue miss was driven by timing of BARDA-related revenues and postponed shipments, while R&D spending rose sharply for the EscharEx Phase III trial. Full-year 2026 revenue guidance of $24-26M was reaffirmed, supported by expected second-half government revenue.

Key Financial Metrics

EPS
−$0.23
Revenue
$1.5M
est $3.4M · -55.9% · -62.7% YoY
Guidance
$24M-$26M
maintained
Gross Margin
21.9%

Key Facts

  • Q1 2026 revenue of $1.5M vs $4.0M in Q1 2025, a 62% decline
  • Net loss of $3.0M ($0.23 per share) vs $0.7M ($0.07 per share) in Q1 2025
  • Full-year 2026 revenue guidance reaffirmed at $24-26M
  • EscharEx Phase III VALUE trial enrollment progressing; interim assessment and enrollment completion expected by end of Q1 2027
  • Vericel awarded a ten-year BARDA contract up to $197M for NexoBrid; initial procurement expected in H2 2026
  • Cash, cash equivalents and deposits totaled $45M as of March 31, 2026, down from $54M at year-end 2025
  • Net cash used in operating activities was $9.6M in Q1 2026

Financial Impact

Revenue decline of $2.5M (62% YoY) and net loss increase of $2.3M; cash burn of $9.6M in operating activities

revenuenet losscash burn

Risk Factors

  • EscharEx Phase III enrollment slower than anticipated; interim results not expected until early 2027
  • Revenue concentration on BARDA contract timing; any delay in government procurement could pressure guidance
  • Expanded NexoBrid manufacturing capacity subject to regulatory approval after EMA pre-audit modifications
  • Cash burn of $9.6M in Q1 2026; cash reserves declining

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3301772

Track record

13 reports on MDWD

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +20.80% at T+60 after the Mar 5, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $12.90 Now $13.55 +5.04% settles Nov 20
  2. Nov 12, 20264d ago 6-K Bearish 6/10 No price data
  3. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $12.97 Now $13.55 −4.47% settles Nov 19
  4. Nov 5, 202611d ago 6-K Bearish 6/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
  6. Nov 3, 202613d ago 424B5 Bearish 5/10 Entry $14.20 to $13.82 Now $13.55 +4.58% ▲ +2.68% +1.76% vs SPY
  7. Sep 22, 20267w ago Press Release Bullish 4/10 Entry $13.95 to $13.80 Now $13.55 −2.87% ▼ −1.08% +0.11% vs SPY
  8. Jun 2, 202623w ago Insider Cluster Bullish 4/10 Entry $13.76 to $14.30 Now $13.55 −1.53% ▲ +3.92% +6.89% vs SPY
  9. May 27, 202624w ago Press Release Bearish 5/10 Viewing Entry $14.33 to $13.73 Now $13.55 +5.44% ▲ +4.19% +4.66% vs SPY
  10. May 7, 202627w ago Press Release Neutral 1/10 Entry $17.27 to $16.25 Now $13.55 −21.54% ▼ −5.91% −7.41% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 27, 2026